Distribuzione geografica
Continente #
EU - Europa 1650
NA - Nord America 1363
AS - Asia 229
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
SA - Sud America 1
Totale 3246
Nazione #
US - Stati Uniti d'America 1360
IE - Irlanda 536
SE - Svezia 515
CN - Cina 217
UA - Ucraina 148
DE - Germania 111
IT - Italia 71
FI - Finlandia 67
GB - Regno Unito 60
FR - Francia 44
PL - Polonia 35
BE - Belgio 30
AT - Austria 16
RU - Federazione Russa 9
VN - Vietnam 6
CA - Canada 3
IN - India 3
EU - Europa 2
NL - Olanda 2
PT - Portogallo 2
CL - Cile 1
ES - Italia 1
HU - Ungheria 1
IR - Iran 1
LB - Libano 1
LV - Lettonia 1
RO - Romania 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 3246
Città #
Dublin 536
Chandler 333
Jacksonville 291
Nyköping 282
Beijing 106
Ann Arbor 85
Dearborn 81
Cambridge 64
Princeton 64
Medford 61
Des Moines 50
Boardman 40
Warsaw 35
Lancaster 34
Brussels 30
Messina 26
Jinan 15
Vienna 14
Wilmington 14
Shenyang 13
Woodbridge 13
Nanjing 11
Nanchang 7
Ningbo 7
San Mateo 7
Dong Ket 6
Grammichele 6
Haikou 6
Hebei 6
Tianjin 6
Guangzhou 5
Hangzhou 5
Taiyuan 5
Helsinki 4
Jiaxing 4
Bremen 3
Catania 3
Clearwater 3
Houston 3
Lanzhou 3
Leawood 3
Reggio Calabria 3
Taizhou 3
Zhengzhou 3
Ashburn 2
Augusta 2
Brooklyn 2
Changsha 2
Fuzhou 2
Lissone 2
Milan 2
Monmouth Junction 2
Montréal 2
New York 2
Norwalk 2
Novokuznetsk 2
Porto 2
Acireale 1
Ardabil 1
Belfast 1
Berlin 1
Budapest 1
Cagliari 1
Cannock 1
Chapel Hill 1
Chicago 1
Delhi 1
Edinburgh 1
Filderstadt 1
Florence 1
Giugliano In Campania 1
Hendon 1
Hillsdale 1
Iasi 1
Istanbul 1
Johannesburg 1
Kemerovo 1
Montreal 1
Mumbai 1
Nanning 1
Pozzo 1
Rüsselsheim 1
Saint Petersburg 1
Serio 1
Simi Valley 1
Stephentown 1
Wenzhou 1
Totale 2355
Nome #
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 82
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 80
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 73
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 72
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 72
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 69
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 65
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 65
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 65
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 62
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 59
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 59
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 58
Embolia polmonare 57
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 55
BRCA1 missense variants of uncertain clinical significance in unaffected and breast/ovarian cancer of the sicilian population. 55
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 54
Breast. La terapia primaria: stato dell'arte 54
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. 53
Tumor Characteristics and Adjuvant treatment in Very Young Women 53
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 53
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 52
Phase II trial ZD1839(IRESSA)second-third line in patients with advanced/metastatic non small cell lung cancer (NSCLC):preliminary results 52
A Missense Mutation Associated to Early Onset Breast Cancer in A Sicilian Woman. 52
null 52
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 52
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 52
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 50
Turbe della nutrizione: anoressia e cachessia. 50
Neoplasie della testa collo nell’ anziano 50
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 49
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 48
Safety of Zoledronic acid in bone metastatic breast cancer patients: A retrospective analysis. 48
A study of a new germline mutation in BRCA1 gene in two Sicilian families: a founder mutation ? 48
Analysis of the expression levels of Leptin gene and it’s receptor in Breast Cancer patients. 47
BRCA1 germline mutations in sicilian breast and/or ovarian cancer families and their implications for genetic counseling. 47
A rare case of malignant solitary fibrous tumor of the spinal cord 47
Strategia Terapeutica nel Carcinoma Prostatico Ormonorefrattario 46
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Sicilian family. 46
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 46
Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy. 45
Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? 45
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 44
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels 43
From Adjuvant to Preventive Breast Cancer Treatment: bridging the gap over troubled waters. 42
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 42
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 41
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience. 41
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 40
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 negative lymphnodes. 39
Infra-centimetric HER2 positive Breast Cancer: The Southern Italy Experience. 39
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 38
AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome 38
Multicenter study in women with infracentimetric HER2 positive breast cancer: The Regional Sicilian experience. 38
null 37
Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. 37
Preclinical Development of an Intracranial Triple Negative Breast Cancer (TNBC) Tumor Model: A Pilot Study. 36
null 33
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 33
Stratifying triple-negative breast cancer: which definition(s) to use? 33
Primary Therapy in Breast Cancer: The State of the Art. 32
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 31
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 28
null 22
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 17
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 14
Totale 3275
Categoria #
all - tutte 6395
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6395

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201870 0000 00 00 00691
2018/201986 1010 568 112 1411
2019/2020555 8235320 384 7577 884795
2020/2021458 6849529 2162 1238 8494131
2021/2022470 56979 213 2313 810766139
2022/20231437 9814662103 96141 3086 64711170
Totale 3275